Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | FHIT | P49789 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
| ▸ | FAP | Q12884 | 1/20 | 0.30 |
| ▸ | CMA1 | P23946 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160897 | 0.83 | HCRTR2 (0.33) | HRH3SMN1; SMN2USP2HCRTR2CMA1 | |
| SCHEMBL5160976 | 0.80 | SMN1; SMN2 (0.37) | SMN1; SMN2USP2 | |
| SCHEMBL3832136 | 0.77 | HSD17B10 (0.38) | SMN1; SMN2USP2HCRTR2DPP4DPP8 | |
| SCHEMBL2490765 | 0.77 | HSD17B10 (0.43) | SMN1; SMN2 | |
| SCHEMBL3771067 | 0.77 | HSD17B10 (0.43) | SMN1; SMN2 | |
| SCHEMBL2566481 | 0.77 | HSD17B10 (0.38) | SMN1; SMN2USP2HCRTR2DPP4DPP8 | |
| SCHEMBL29039261 | 0.77 | HSD17B10 (0.43) | SMN1; SMN2 | |
| SCHEMBL5160339 | 0.74 | HCRTR2 (0.32) | HRH3SMN1; SMN2HCRTR2CMA1 | |
| SCHEMBL3763846 | 0.74 | PDE8B (0.43) | SMN1; SMN2 | |
| SCHEMBL2567398 | 0.74 | HSD17B10 (0.34) | SMN1; SMN2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | HRH3 468/4885SMN1; SMN2 3016/4885FHIT 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.